Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection
Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications spec...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | info:ar-repo/semantics/artículo |
| Lenguaje: | Inglés |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12123/16367 https://www.mdpi.com/1999-4915/14/11/2371 https://doi.org/10.3390/v14112371 |
| _version_ | 1855037474172043264 |
|---|---|
| author | Artman, Chad Idegwu, Nnebuefe Brumfield, Kyle D. Lai, Ken Hauta, Shirley Falzarano, Darryl Parreño, Gladys Viviana Yuan, Lijuan Geyer, James D. Goepp, Julius G. |
| author_browse | Artman, Chad Brumfield, Kyle D. Falzarano, Darryl Geyer, James D. Goepp, Julius G. Hauta, Shirley Idegwu, Nnebuefe Lai, Ken Parreño, Gladys Viviana Yuan, Lijuan |
| author_facet | Artman, Chad Idegwu, Nnebuefe Brumfield, Kyle D. Lai, Ken Hauta, Shirley Falzarano, Darryl Parreño, Gladys Viviana Yuan, Lijuan Geyer, James D. Goepp, Julius G. |
| author_sort | Artman, Chad |
| collection | INTA Digital |
| description | Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway. |
| format | info:ar-repo/semantics/artículo |
| id | INTA16367 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI |
| publisherStr | MDPI |
| record_format | dspace |
| spelling | INTA163672023-12-27T14:36:04Z Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection Artman, Chad Idegwu, Nnebuefe Brumfield, Kyle D. Lai, Ken Hauta, Shirley Falzarano, Darryl Parreño, Gladys Viviana Yuan, Lijuan Geyer, James D. Goepp, Julius G. Norovirus Caliciviridae Foodborne Disease Gastroenteritis Enfermedades Transmitidas por Alimentos Polyclonal Avian Immunoglobulins Human Norovirus Infection Prophylaxis Outbreak Prevention and Control Inmunoglobulinas Aviares Policlonales Infección por Norovirus Humano Profilaxis Prevención y Control de Brotes Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway. Instituto de Virología Fil: Artman, Chad. Scaled Microbiomics; Estados Unidos Fil: Idegwu, Nnebuefe. Scaled Microbiomics; Estados Unidos Fil: Brumfield, Kyle D. College Park Campus. University of Maryland. Maryland Pathogen Research Institute; Estados Unidos Fil: Brumfield, Kyle D. College Park Campus. University of Maryland. University of Maryland Institute for Advanced Computer Studies; Estados Unidos Fil: Lai, Ken. University of Saskatchewan. Vaccine and Infectious Disease Organization; Canadá Fil: Hauta, Shirley. University of Saskatchewan. Vaccine and Infectious Disease Organization; Canadá Fil: Falzarano, Darryl. University of Saskatchewan. Vaccine and Infectious Disease Organization; Canadá Fil: Falzarano, Darryl. University of Saskatchewan. Western College of Veterinary Medicine. Department of Veterinary Microbiology; Canadá Fil: Parreño, Gladys Viviana. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos Fil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria (INTA). INCUINTA. Instituto de Virologia e Innovaciones Tecnologicas (IVIT); Argentina Fil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos Fil: Geyer, James D. University of Alabama. College of Community Health Science. Institute for Rural Health Research; Estados Unidos Fil: Goepp, Julius G. Scaled Microbiomics; Estados Unidos 2023-12-27T14:29:53Z 2023-12-27T14:29:53Z 2022-11 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/16367 https://www.mdpi.com/1999-4915/14/11/2371 1999-4915 https://doi.org/10.3390/v14112371 eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf MDPI Viruses 14 (11) : 2371 (2022) |
| spellingShingle | Norovirus Caliciviridae Foodborne Disease Gastroenteritis Enfermedades Transmitidas por Alimentos Polyclonal Avian Immunoglobulins Human Norovirus Infection Prophylaxis Outbreak Prevention and Control Inmunoglobulinas Aviares Policlonales Infección por Norovirus Humano Profilaxis Prevención y Control de Brotes Artman, Chad Idegwu, Nnebuefe Brumfield, Kyle D. Lai, Ken Hauta, Shirley Falzarano, Darryl Parreño, Gladys Viviana Yuan, Lijuan Geyer, James D. Goepp, Julius G. Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection |
| title | Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection |
| title_full | Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection |
| title_fullStr | Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection |
| title_full_unstemmed | Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection |
| title_short | Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection |
| title_sort | feasibility of polyclonal avian immunoglobulins igy as prophylaxis against human norovirus infection |
| topic | Norovirus Caliciviridae Foodborne Disease Gastroenteritis Enfermedades Transmitidas por Alimentos Polyclonal Avian Immunoglobulins Human Norovirus Infection Prophylaxis Outbreak Prevention and Control Inmunoglobulinas Aviares Policlonales Infección por Norovirus Humano Profilaxis Prevención y Control de Brotes |
| url | http://hdl.handle.net/20.500.12123/16367 https://www.mdpi.com/1999-4915/14/11/2371 https://doi.org/10.3390/v14112371 |
| work_keys_str_mv | AT artmanchad feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection AT idegwunnebuefe feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection AT brumfieldkyled feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection AT laiken feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection AT hautashirley feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection AT falzaranodarryl feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection AT parrenogladysviviana feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection AT yuanlijuan feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection AT geyerjamesd feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection AT goeppjuliusg feasibilityofpolyclonalavianimmunoglobulinsigyasprophylaxisagainsthumannorovirusinfection |